157 related articles for article (PubMed ID: 36892150)
1. Practical Guidance for the Management of Adverse Events in Patients with KRASG12C-Mutated Non-Small Cell Lung Cancer Receiving Adagrasib.
Zhang J; Johnson M; Barve M; Bazhenova L; McCarthy M; Schwartz R; Horvath-Walsh E; Velastegui K; Qian C; Spira A
Oncologist; 2023 Apr; 28(4):287-296. PubMed ID: 36892150
[TBL] [Abstract][Full Text] [Related]
2. Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non-Small Cell Lung Cancer.
Sabari JK; Velcheti V; Shimizu K; Strickland MR; Heist RS; Singh M; Nayyar N; Giobbie-Hurder A; Digumarthy SR; Gainor JF; Rajan AP; Nieblas-Bedolla E; Burns AC; Hallin J; Olson P; Christensen JG; Kurz SC; Brastianos PK; Wakimoto H
Clin Cancer Res; 2022 Aug; 28(15):3318-3328. PubMed ID: 35404402
[TBL] [Abstract][Full Text] [Related]
3. Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Trial With
Negrao MV; Spira AI; Heist RS; Jänne PA; Pacheco JM; Weiss J; Gadgeel SM; Velastegui K; Yang W; Der-Torossian H; Christensen JG; Sabari JK
J Clin Oncol; 2023 Oct; 41(28):4472-4477. PubMed ID: 37327468
[No Abstract] [Full Text] [Related]
4. First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced
Ou SI; Jänne PA; Leal TA; Rybkin II; Sabari JK; Barve MA; Bazhenova L; Johnson ML; Velastegui KL; Cilliers C; Christensen JG; Yan X; Chao RC; Papadopoulos KP
J Clin Oncol; 2022 Aug; 40(23):2530-2538. PubMed ID: 35167329
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer.
Yaeger R; Uboha NV; Pelster MS; Bekaii-Saab TS; Barve M; Saltzman J; Sabari JK; Peguero JA; Paulson AS; Jänne PA; Cruz-Correa M; Anderes K; Velastegui K; Yan X; Der-Torossian H; Klempner SJ; Kopetz SE
Cancer Discov; 2024 Jun; 14(6):982-993. PubMed ID: 38587856
[TBL] [Abstract][Full Text] [Related]
6. Adagrasib in Non-Small-Cell Lung Cancer Harboring a
Jänne PA; Riely GJ; Gadgeel SM; Heist RS; Ou SI; Pacheco JM; Johnson ML; Sabari JK; Leventakos K; Yau E; Bazhenova L; Negrao MV; Pennell NA; Zhang J; Anderes K; Der-Torossian H; Kheoh T; Velastegui K; Yan X; Christensen JG; Chao RC; Spira AI
N Engl J Med; 2022 Jul; 387(2):120-131. PubMed ID: 35658005
[TBL] [Abstract][Full Text] [Related]
7. Adagrasib Response Remains Strong in NSCLC.
Cancer Discov; 2022 Aug; 12(8):OF1. PubMed ID: 35666594
[TBL] [Abstract][Full Text] [Related]
8. Trials, Tribunals, and Opportunities for Lung Cancer KRASG12C Brain Metastases.
Kommalapati A; Mansfield AS
Clin Cancer Res; 2022 Aug; 28(15):3179-3181. PubMed ID: 35608481
[TBL] [Abstract][Full Text] [Related]
9. Adagrasib's Efficacy Sustained in KRASG12C NSCLC.
Cancer Discov; 2023 Nov; 13(11):OF1. PubMed ID: 37702568
[TBL] [Abstract][Full Text] [Related]
10. Safety and Intracranial Activity of Adagrasib in Patients With
Bernstein E; Luo J; Wang K; Negrao MV; Jänne PA; Sabari JK
JCO Precis Oncol; 2024 Feb; 8():e2300447. PubMed ID: 38330263
[No Abstract] [Full Text] [Related]
11. Management of sotorasib-related adverse events and hepatotoxicities following anti-PD-(L)1 therapy: Experience with sotorasib in two French anti-cancer centers and practical guidance proposal.
Chour A; Basse C; Lebossé F; Bonte PE; Girard N; Duruisseaux M
Lung Cancer; 2024 May; 191():107789. PubMed ID: 38614068
[TBL] [Abstract][Full Text] [Related]
12. A saturation mutagenesis screen uncovers resistant and sensitizing secondary
Feng S; Callow MG; Fortin JP; Khan Z; Bray D; Costa M; Shi Z; Wang W; Evangelista M
Proc Natl Acad Sci U S A; 2022 May; 119(18):e2120512119. PubMed ID: 35471904
[TBL] [Abstract][Full Text] [Related]
13. Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study.
Ahn MJ; Kim DW; Cho BC; Kim SW; Lee JS; Ahn JS; Kim TM; Lin CC; Kim HR; John T; Kao S; Goldman JW; Su WC; Natale R; Rabbie S; Harrop B; Overend P; Yang Z; Yang JC
Lancet Respir Med; 2017 Nov; 5(11):891-902. PubMed ID: 29056570
[TBL] [Abstract][Full Text] [Related]
14. Limited role of
Li HS; Liu CM; Wang Y
Future Oncol; 2022 Jun; 18(19):2433-2443. PubMed ID: 35440164
[TBL] [Abstract][Full Text] [Related]
15. First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer
Niu J; Maurice-Dror C; Lee DH; Kim DW; Nagrial A; Voskoboynik M; Chung HC; Mileham K; Vaishampayan U; Rasco D; Golan T; Bauer TM; Jimeno A; Chung V; Chartash E; Lala M; Chen Q; Healy JA; Ahn MJ
Ann Oncol; 2022 Feb; 33(2):169-180. PubMed ID: 34800678
[TBL] [Abstract][Full Text] [Related]
16. Adagrasib: First Approval.
Dhillon S
Drugs; 2023 Feb; 83(3):275-285. PubMed ID: 36763320
[TBL] [Abstract][Full Text] [Related]
17. Frontline Promise for Adagrasib-Pembrolizumab Combination.
Cancer Discov; 2023 Feb; 13(2):OF2. PubMed ID: 36541865
[TBL] [Abstract][Full Text] [Related]
18. Management of ceritinib therapy and adverse events in patients with ALK-rearranged non-small cell lung cancer.
Califano R; Greystoke A; Lal R; Thompson J; Popat S
Lung Cancer; 2017 Sep; 111():51-58. PubMed ID: 28838397
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Limertinib (ASK120067) in Patients With Locally Advanced or Metastatic EGFR Thr790Met-Mutated NSCLC: A Multicenter, Single-Arm, Phase 2b Study.
Shi Y; Li B; Wu L; Pan Y; Pan Z; Liu Y; Fan Y; Ji Y; Fang J; Shi Q; Shi J; Gao H; Hu Y; Wang X; He Z; Ma R; Zhang Y; Jiang D; Bai Y; Zhang Y; Huang L; Zhou T; Liu H; Wang D; Wen Q; Chen G; Zang A; Wang X; Zhang X; Hu J; Yang R; Zhang G; Gu K; Wang L; Wang Q; Wei Z; Li Z; Lu H; Zhang H; Chen H; Song T
J Thorac Oncol; 2022 Oct; 17(10):1205-1215. PubMed ID: 35659581
[TBL] [Abstract][Full Text] [Related]
20.
Ceddia S; Landi L; Cappuzzo F
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012655
[No Abstract] [Full Text] [Related]
[Next] [New Search]
